Although the results of this educational intervention were promising, there is evidence that interventions that are individually-tailored to ESRD patients' needs and preferences may be even more successful at reducing racial disparities in completion of evaluation and receipt of LDKTs [ 34, 35].
Completion of transplant evaluation and receipt of LDKT will be assessed for both groups using medical records 18-months post-baseline.
Changes in transplant knowledge, readiness, pros and cons, and self-efficacy to pursue LDKT will be assessed prior to presenting at the transplant center (baseline), during transplant evaluation, and 4- and 8-months post-baseline, while completion of transplant evaluation and receipt of LDKTs will be assessed at 18-months post-baseline.
Figure 1 outlines the course of the Phase II trial after completion of the Screening/Baseline period and receipt of study drugs at week 0. Patients will be evaluated after 2, 8, 16, and 26 weeks of the assigned experimental treatment.
Completion of the self-administered questionnaire and receipt of the blood sample were considered to imply informed consent.
Immediately after completion of baseline pedometer data collection and receipt of the medical clearance, the participants are automatically randomized to one of two arms: 1) Internet-mediated, pedometer-enhanced program (Taking Healthy Steps) or 2) Wait list control.
Cox proportional hazard regression models were used to determine the independent effect of group type (2-FIT vs. 1-FIT) on the completion of the FIT, adjusting for age, sex, and receipt of prior CRC screening.
Older age and receipt of prior CRC screening were associated with FIT completion in both groups, a finding consistent with previous research (Mosen et al., 2010).
The 2-FIT group had lower test completion rates (hazard ratio=0.87; 95% confidence interval=0.78 0.97; P=0.01) after adjusting for age, sex, and receipt of prior CRC screening.
